It is possible that this trend is due, at least in part, to the off-label use of diabetes-approved GLP-1 RAs for weight loss in patients without diabetes
Stir well until fully dissolved
So at this time, it's premature to provide a provide a specific revenue impact
However, CJC-1295 (especially the DAC version) can cause sustained elevation in IGF-1, whichif mismanagedmay increase the risk of: Insulin resistance Carpal tunnel syndrome Soft tissue growth (in rare, prolonged cases) Pituitary overstimulation That said, these issues are more often associated with excessive dosing or continuous high-frequency use
That does not make discussion irresponsible
Because GLP- is rapidly inactivated by the enzymatic cleavage of dipeptidyl peptidase- (DPP) long-acting GLP- analogues, for example, exenatide and DPP inhibitors, for example, liraglutide, have been developed as therapeutics for type diabetes mellitus (TDM)